Welcome to our dedicated page for Anika Therapeutics news (Ticker: ANIK), a resource for investors and traders seeking the latest updates and insights on Anika Therapeutics stock.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global joint preservation company focused on early intervention orthopedics, osteoarthritis (OA) pain management, and regenerative solutions based on hyaluronic acid and implant technologies. This news page aggregates company-issued updates and market-moving announcements so readers can follow how Anika’s clinical programs, product portfolio, and financial performance evolve over time.
News about Anika commonly covers quarterly and annual financial results, including performance in its Commercial Channel and OEM Channel, as well as commentary on operating expenses, cost-saving measures, and capital allocation decisions such as share repurchase programs. Investors can also find updates on governance and compensation topics, including amendments to equity incentive plans and inducement grants made under Nasdaq Listing Rule 5635(c)(4).
A significant portion of Anika’s news flow focuses on clinical and regulatory milestones for its key products. Examples include updates on the U.S. pivotal Phase III FastTRACK study for the Hyalofast cartilage repair scaffold, the filing of the third and final PMA module for Hyalofast with the U.S. Food and Drug Administration, and progress toward a U.S. New Drug Application for Cingal, the company’s non-opioid, single-injection OA pain management product. Releases also describe commercial milestones, such as Cingal surpassing one million injections worldwide and the growth trajectory of the Integrity Implant System.
Corporate and leadership developments are another recurring theme. Anika issues press releases on planned leadership transitions, board changes, and strategic refocusing around its hyaluronic acid portfolio and regenerative solutions. By reviewing the ANIK news stream on this page, readers can monitor how clinical data, regulatory submissions, commercial performance, and governance actions shape the company’s position in osteoarthritis pain management and orthopedic regenerative medicine.
Anika Therapeutics (NASDAQ:ANIK) has reported topline results from its FastTRACK Phase III study for Hyalofast®, a cartilage repair scaffold. While the treatment showed consistent improvements over microfracture, it missed the pre-specified co-primary endpoints for KOOS Pain and IKDC function statistical significance.
Despite this setback, Hyalofast demonstrated statistically significant improvements in secondary endpoints, including KOOS Sports and Recreation Function, Quality of Life, and Total KOOS. The product has been successfully used in over 35,000 patients across 35+ countries since 2009. Anika plans to file the final PMA module in H2 2025, incorporating additional post-hoc analyses and global data under its Breakthrough Device Designation.
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company focused on early intervention orthopedics, has scheduled its second quarter 2025 financial results announcement for Wednesday, July 30, 2025. The results will be released before market opening, followed by a conference call at 8:30 a.m. ET.
Investors can access the conference call via phone (toll-free: 1-800-717-1738 or international: 1-646-307-1865) using conference ID 48251. A live webcast and presentation materials will be available on Anika's investor relations website, with an archived version accessible after the call.
[]Anika Therapeutics (NASDAQ: ANIK), a leader in osteoarthritis pain management and regenerative solutions, has announced inducement grants to a new non-executive employee. The company granted 2,500 non-statutory stock options at an exercise price of $10.53 per share on July 1, 2025.
The options were granted under the Anika Therapeutics 2021 Inducement Plan, with one-third of the shares vesting annually over three years, contingent on continuous service. The options will expire after ten years and were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Anika Therapeutics (NASDAQ: ANIK) announced the granting of non-statutory stock options to two newly hired non-executive employees on May 1, 2025. The options cover 5,000 shares of common stock at an exercise price of $14.46 per share, matching the closing price on the Nasdaq Global Select Market on the grant date. The options were granted under the company's 2021 Inducement Plan and will vest in three equal annual installments over three years, contingent on continuous service. The options expire after ten years and were approved as material inducement for employment compensation.
Anika Therapeutics (NASDAQ: ANIK), a leader in osteoarthritis pain management and regenerative solutions, has announced its participation in the upcoming Sidoti Virtual Investor Conference. The company's management will deliver a virtual presentation followed by a Q&A session on Wednesday, May 21, 2025, at 1:00 PM ET. Investors can access the live webcast through Anika's Investor Relations website section at www.anika.com, where an archived version will also be available for later viewing.
Anika Therapeutics (NASDAQ: ANIK), a global joint preservation company specializing in early intervention orthopedics, has scheduled the release of its first quarter 2025 financial results before market opening on Friday, May 9, 2025.
The company will host a conference call at 8:30 a.m. ET to discuss the results and business highlights. Investors can join via phone using toll-free domestic (1-800-717-1738) or international (1-646-307-1865) numbers with conference ID 63463. A live audio webcast with presentation materials will be available on Anika's website investor relations section.
Anika Therapeutics (NASDAQ: ANIK) has announced the granting of non-statutory stock options to a newly hired non-executive employee on April 1, 2025. The options cover 3,800 shares of common stock with an exercise price of $15.03 per share, matching the closing price on Nasdaq Global Select Market on the grant date.
The options were granted under the Anika Therapeutics 2021 Inducement Plan and approved by the compensation committee. The vesting schedule includes one-third of the shares vesting on each of the first three anniversaries of the grant date, contingent on continuous service. The options will expire after ten years and were granted as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).
Anika Therapeutics (NASDAQ: ANIK) reported Q4 2024 revenue of $30.6 million, up 1% year-over-year, with full-year 2024 revenue at $119.9 million, down 1% from 2023.
The Commercial Channel showed strong performance with 25% growth in Q4 and 17% annual growth, driven by the Integrity Implant System (>40% sequential growth) and International OA Pain Management. The OEM Channel declined 8% as expected.
Key highlights include:
- Over 300 Integrity surgeries performed in Q4, totaling 1,000+ globally since launch
- Filed second PMA module for Hyalofast with US launch anticipated by 2026
- Completed sale of Parcus Medical to focus on core HA products
- Completed $15M share repurchase program ahead of schedule
For 2025 guidance, Anika expects Commercial Channel revenue growth of 12-18% ($47-49.5M) and OEM Channel revenue decline of 12-18% ($64-68.5M). Adjusted EBITDA margin is projected at 8-10%.